Larimar Therapeutics Return on Equity

Larimar Therapeutics (LRMR) currently reports a ROE of -135.5%. That is below the Healthcare sector average of 22.01%. Use the charts on this page to explore Larimar Therapeutics's ROE history and peer comparisons.

Larimar Therapeutics's ROE of -135.5% is lower than the Healthcare sector average of 22.01%. That is roughly 715.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Larimar Therapeutics's current -135.5% should be judged against Healthcare norms (sector average: 22.01%) and against LRMR's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -135.5%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.01%. From there, open related valuation or income-statement pages for Larimar Therapeutics, and consider following LRMR for alerts when major investors trade the stock.

Larimar Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -135.5% versus a sector average near 22.01%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LRMR with unrelated industries.